| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
1,6-Diphenylhexa-1,3,5-triene targets biological membranes, specifically the hydrophobic core of lipid bilayers. It intercalates into the acyl chain region of membrane phospholipids, where its fluorescence properties are sensitive to the membrane’s physical state, such as fluidity and order. The probe does not bind to a specific protein receptor but rather partitions into the membrane environment.
|
|---|---|
| ln Vitro |
In vitro, DPH is used to measure membrane fluidity in model membranes (liposomes) and biological membranes (cells, isolated membranes). Its fluorescence anisotropy or polarization is measured to assess the rotational mobility of the probe within the membrane, which correlates with membrane order and fluidity. DPH is also used to study lipid phase transitions and the effects of various agents on membrane structure.
|
| ln Vivo |
There are no significant in vivo applications for DPH as it is primarily an in vitro probe for membrane studies. It is not a therapeutic agent.
|
| Enzyme Assay |
The in vitro assay for DPH involves incorporating the probe into membranes or liposomes and measuring fluorescence anisotropy or polarization. DPH is excited at a specific wavelength, and the emitted fluorescence is measured at a longer wavelength. The anisotropy value reflects the rotational freedom of the probe, which is inversely related to membrane fluidity. The probe’s high photostability and sensitivity make it suitable for these measurements.
|
| Cell Assay |
For in vitro cell-based assays, cells are incubated with DPH, which partitions into the plasma membrane. Fluorescence anisotropy is then measured using a fluorometer or fluorescence microscope to assess membrane fluidity. The effects of drugs, temperature changes, or genetic modifications on membrane properties can be evaluated.
|
| Animal Protocol |
There are no standard in vivo animal experimental protocols for DPH as it is not administered to live animals for therapeutic or pharmacokinetic studies. It is a research tool for in vitro membrane biophysics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DPH are not characterized as it is not a drug. It is a fluorescent probe for research use.
|
| Toxicity/Toxicokinetics |
No toxicity data for DPH are available. As a research chemical, it should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
A fluorescent compound that emits light only in a specific lipid medium in a specific configuration. It is used as a tool for studying membrane lipids.
1,6-Diphenylhexa-1,3,5-triene (DPH) is a fluorescent probe used to study membrane dynamics and fluidity. It embeds within lipid bilayers and exhibits environment-sensitive fluorescence. It is for research use only. Its CAS number is 1720-32-7. |
| Molecular Formula |
C18H16
|
|---|---|
| Molecular Weight |
232.31964
|
| Exact Mass |
232.125
|
| CAS # |
1720-32-7
|
| PubChem CID |
10868176
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.028g/cm3
|
| Boiling Point |
407.2ºC at 760mmHg
|
| Melting Point |
199-203 °C(lit.)
|
| Flash Point |
221ºC
|
| Vapour Pressure |
4.44E-05mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
4.969
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
253
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)/C=C/C=C/C=C\C2=CC=CC=C2
|
| InChi Key |
BOBLSBAZCVBABY-WSRJZADISA-N
|
| InChi Code |
InChI=1S/C18H16/c1(5-11-17-13-7-3-8-14-17)2-6-12-18-15-9-4-10-16-18/h1-16H/b2-1+,11-5-,12-6+
|
| Chemical Name |
[(1Z,3E,5E)-6-phenylhexa-1,3,5-trienyl]benzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~14.29 mg/mL (~61.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3044 mL | 21.5220 mL | 43.0441 mL | |
| 5 mM | 0.8609 mL | 4.3044 mL | 8.6088 mL | |
| 10 mM | 0.4304 mL | 2.1522 mL | 4.3044 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
